Retatrutide for Knee Osteoarthritis: A Breakthrough Treatment That’s Changing the Future of Joint Pain Management

4

Key Takeaways :

Use of Retatrutide for Knee Osteoarthritis is still under research and waiting for an approval from FDA.

What It Is: Retatrutide is an investigational once-weekly injectable medication that works as a “triple agonist” , simultaneously targeting GLP-1, GIP, and glucagon hormone receptors to produce powerful metabolic effects.

The Breakthrough: In the Phase 3 TRIUMPH-4 clinical trial (445 participants, 68 weeks), retatrutide achieved:

• 75.8% average reduction in knee pain (vs. 40.3% with placebo)
• 28.7% total body weight loss (71.2 lbs average) on the 12 mg dose
• 14.1% of participants became completely pain-free, their WOMAC pain score fell to zero
• 71-73% improvement in physical function (walking, climbing stairs, standing)

How It Works: Retatrutide addresses knee osteoarthritis through two complementary mechanisms:

1. Mechanical unloading – dramatic weight loss removes hundreds of pounds of daily compressive force from damaged joints
2. Anti-inflammatory action – reduced fat tissue lowers circulating inflammatory cytokines, while GLP-1/glucagon pathways directly reduce joint inflammation

Current Status: Retatrutide remains investigational and is NOT yet FDA-approved. Regulatory submission is expected in 2027, with potential commercial availability in 2027-2028. Patients should NOT use unregulated online “research chemicals.”

Why It Matters: For the first time, a medical therapy offers the potential to dramatically reduce knee osteoarthritis pain while addressing the root metabolic drivers of the disease – offering hope for avoiding or delaying joint replacement surgery.

For millions of people living with knee osteoarthritis, daily life is defined by a constant, wearing pain that seeps into every aspect of existence. Simple acts that most people take for granted, walking down a flight of stairs, getting out of a chair after a meal, going for an evening stroll with a spouse, or even standing long enough to prepare dinner, can turn into grueling, exhausting tasks that drain both physical and emotional energy.

The World Health Organization estimates that over 365 million people worldwide live with osteoarthritis, with the knee being the most commonly affected joint. In the United States alone, approximately 14 million adults suffer from symptomatic knee osteoarthritis, a number that continues to rise as the population ages and obesity rates climb.

For decades, medicine offered limited remedies for this debilitating condition. The standard arsenal included temporary pain relievers that came with their own dangerous side effects, physical therapy that many patients couldn’t tolerate due to pain, weight-management advice that proved nearly impossible to follow without medical assistance, and ultimately, major surgical joint replacement, a procedure that, while effective, requires significant recovery time, carries infection risks, and leaves patients with artificial joints that typically last only 15 to 20 years before requiring complex revision surgeries.

However, a massive shift is underway at the intersection of metabolic science and joint health, a convergence that few medical experts could have predicted even a decade ago. In late 2025, pharmaceutical innovator Eli Lilly and Company released groundbreaking Phase 3 clinical trial results from its TRIUMPH-4 study, sending shockwaves through the medical community and offering new hope to millions of sufferers worldwide. The trial evaluated an experimental once-weekly injectable molecule called retatrutide in adults living with obesity and knee osteoarthritis, and the findings were nothing short of revolutionary.

The results demonstrated that retatrutide did not just deliver unprecedented weight loss, it cut knee osteoarthritis pain by an average of 75.8%. Even more remarkable, a significant portion of participants experienced complete relief from their chronic knee pain by the end of the 68-week trial, achieving a pain score of zero on standardized pain scales. These findings represent a potential paradigm shift in how we understand and treat joint disease, moving beyond symptom management to addressing the root biological and mechanical drivers of osteoarthritis.

This comprehensive analysis explores the intricate science of knee osteoarthritis, the revolutionary mechanisms behind retatrutide’s triple-agonist action, the deep specifics of the TRIUMPH-4 study design and execution, the brilliant minds and institutions behind this scientific breakthrough, the safety profile that patients need to understand, and why, despite these astounding findings, retatrutide is not yet available at your local pharmacy. By the end of this exploration, readers will understand not just what this breakthrough means for knee osteoarthritis, but how it exemplifies a new era of metabolic medicine that addresses chronic disease at its biological roots.

What Is Knee Osteoarthritis and Why Does It Happen?

To understand why a metabolic drug can relieve joint pain, one must first look at the intricate mechanics and biology of knee osteoarthritis (OA), a disease that is far more complex than simple “wear and tear.”

The Anatomy and Mechanics of the Knee Joint

The knee is one of the largest and most complex weight-bearing joints in the human body, a remarkable biological engineering feat that must balance stability with mobility. It acts as a hinge where the femur (thighbone), the longest and strongest bone in the body, meets the tibia (shinbone), which bears the majority of body weight. The patella (kneecap) glides along a groove in the femur, providing leverage for the quadriceps muscles.

To keep these bones from grinding against each other during the thousands of steps we take each day, the ends of the bones are capped with a slick, resilient tissue called articular cartilage. This specialized tissue, which is only 2 to 4 millimeters thick in the knee, is composed primarily of water (up to 80% in young adults), collagen fibers (primarily type II collagen), and proteoglycans large molecules that trap water and give cartilage its springy, shock-absorbing properties. This cartilage, along with a lubricating fluid called synovial fluid that is produced by the synovial membrane lining the joint capsule, allows the joint to move smoothly with minimal friction.

How Osteoarthritis Develops: A Multifactorial Process

Knee osteoarthritis is a progressive, degenerative joint disease that affects the entire joint structure, not just the cartilage. It is increasingly understood as a disease of the whole joint, including the subchondral bone, synovium, menisci, ligaments, and surrounding muscles. The disease process unfolds through several interrelated mechanisms:

Cartilage Degradation 

Over time, the smooth protective cartilage wears away through a combination of mechanical and biochemical factors. The cartilage matrix begins to break down as chondrocytes, the only cells present in cartilage, attempt to repair damage but ultimately fail due to the tissue’s limited blood supply and the overwhelming nature of the damage. As the cartilage thins and breaks down, several cascading effects occur. Bones begin to rub directly against bone, causing raw friction and exposing nerve endings in the subchondral bone. The joint structure responds to the instability by growing rough bony projections called bone spurs (osteophytes) along the margins of the joint. The inner lining of the joint capsule (the synovium) becomes inflamed and swollen, releasing pro-inflammatory cytokines that further accelerate cartilage breakdown. The joint stiffens, swells, and loses its full range of motion, creating a vicious cycle where limited mobility leads to muscle weakness, which further destabilizes the joint.

The Role of Aging 

While osteoarthritis is not simply a consequence of aging, increasing age is the single strongest risk factor. By age 65, over 50% of adults have radiographic evidence of knee osteoarthritis, though many may not experience symptoms. The aging process affects cartilage in multiple ways. Chondrocytes become less responsive to growth factors and more prone to apoptosis (programmed cell death). The water content of cartilage decreases, reducing its shock-absorbing capacity. The concentration of proteoglycans in the cartilage matrix declines, and the collagen network becomes increasingly disorganized and cross-linked. Age-related muscle loss (sarcopenia) reduces the protective muscular support around joints, and the body’s repair mechanisms become less efficient.

The Devastating Impact of Obesity on Joint Health

Obesity is one of the single largest preventable risk factors for developing and accelerating knee osteoarthritis. The relationship between excess weight and joint damage is so strong that researchers now refer to it as a “dose-response relationship,” meaning the higher the body mass index (BMI), the greater the risk and severity of osteoarthritis. This relationship operates through two distinct but interconnected forces:

Biomechanical Overload (Physical Load) 

The biomechanical impact of excess weight on the knee joint is staggering. Research has shown that when you walk, every single step exerts a force on your knees equal to approximately 3 to 6 times your total body weight. This means a person weighing 200 pounds places between 600 and 1,200 pounds of compressive force across the knee with each step. Carrying an extra 30 pounds adds an extra 90 to 180 pounds of pressure across the knee joint with every single step. Every 11 pounds of weight gained increases the risk of developing knee osteoarthritis by roughly 36%, according to data from the Framingham Heart Study. Over years and decades, this relentless physical pounding breaks down cartilage cells faster than the body can repair them. The impact is particularly concentrated on the medial (inner) compartment of the knee, which bears the majority of body weight during walking. This explains why obesity is such a strong risk factor for medial compartment osteoarthritis the most common form of the disease.

Systemic Metabolic Inflammation (Chemical Stress) 

Perhaps less intuitive but equally important is the biochemical impact of excess body fat. Adipose tissue (fat tissue) is not just an inert storage depot for excess calories; it is an active, hormone-producing organ that secretes numerous biologically active molecules called adipokines. Excess fat cells release low-grade, constant chemical messengers called pro-inflammatory cytokines (such as interleukin-6, TNF-alpha, and leptin) into the bloodstream. These circulating inflammatory chemicals travel through the blood to joint cartilage, accelerating cartilage breakdown through several mechanisms. They activate enzymes called matrix metalloproteinases (MMPs) that directly degrade collagen and proteoglycans in cartilage. They increase the production of prostaglandins and other inflammatory mediators that sensitize pain receptors in the joint. They even affect the central nervous system, lowering the pain threshold and making patients more sensitive to pain signals from their joints. This systemic inflammation explains why osteoarthritis is increasingly recognized as a metabolic disease and why people with obesity often develop joint pain even in non-weight-bearing joints like the hands and wrists.

The Vicious Cycle of Pain and Inactivity 

One of the most devastating aspects of knee osteoarthritis is the self-perpetuating cycle it creates. Pain makes exercise difficult, leading to muscle weakness, particularly in the quadriceps, which are crucial for stabilizing the knee. Muscle weakness, in turn, places additional stress on the joint, accelerating cartilage breakdown. Weight gain often accompanies reduced activity, adding further mechanical stress. The result is a downward spiral that becomes increasingly difficult to break without significant medical intervention. This cycle explains why traditional approaches focusing solely on exercise or weight loss often fail the pain makes the necessary therapeutic activities nearly impossible.

The Traditional Way of Treating Knee Osteoarthritis (And Its Limits)

Before exploring the revolutionary potential of retatrutide, it helps to thoroughly review how doctors currently treat knee osteoarthritis. This understanding highlights why the TRIUMPH-4 results represent such a significant breakthrough.

The Conventional Treatment Arsenal

Over-the-Counter and Prescription Pain Relievers: Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, naproxen, and the prescription medication celecoxib are the first-line pharmacological treatment for knee osteoarthritis. These drugs work by inhibiting cyclooxygenase (COX) enzymes, which are responsible for producing prostaglandins that cause inflammation and pain. However, long-term daily use of NSAIDs carries significant risks. The COX-1 inhibition in traditional NSAIDs can lead to stomach ulcers and gastrointestinal bleeding, with studies estimating that NSAID-related gastrointestinal complications cause over 100,000 hospitalizations and 16,500 deaths annually in the United States. Even COX-2 selective inhibitors, while safer on the stomach, have been linked to increased cardiovascular risks, including heart attacks and strokes. Additionally, research increasingly suggests that long-term NSAID use may actually accelerate cartilage loss by inhibiting the natural repair processes that depend on prostaglandins.

Corticosteroid Injections 

Doctors often inject steroid medications directly into the knee capsule to calm localized inflammation. These injections can provide dramatic but temporary relief, typically lasting from several weeks to a few months. However, the benefits are often short-lived, and repeated steroid injections over time can actually accelerate cartilage damage and weaken joint tissues. A 2019 study in the Journal of the American Medical Association found that patients receiving intra-articular corticosteroids for knee osteoarthritis actually had greater cartilage loss over two years compared to those receiving placebo injections. This finding has led many orthopedic surgeons to recommend steroid injections sparingly, particularly in younger patients.

Hyaluronic Acid (Viscosupplementation) Injections 

These treatments, often called “gel injections,” involve injecting synthetic lubricating fluids (viscosupplements) into the joint space to restore the viscoelastic properties of synovial fluid. The idea is to improve joint lubrication and provide a shock-absorbing cushion. However, clinical trial results for these treatments have been mixed. While some patients report significant benefit, meta-analyses suggest that the effects are modest at best and that these injections provide no more than a placebo effect in many patients. Additionally, the treatments are expensive and not consistently covered by insurance.

Physical Therapy and Exercise 

Strengthening the quadriceps and hamstring muscles helps stabilize the knee joint and absorb impact. This remains a critical foundation of care, with evidence showing that muscle strengthening can reduce pain and improve function. However, severe pain often stops patients from exercising effectively. A 2019 systematic review found that while physical therapy provides modest benefits for knee osteoarthritis, the effect sizes are generally small, and many patients struggle to maintain exercise regimens due to pain or lack of motivation. The challenge is compounded by the fact that many patients with knee osteoarthritis also have other health conditions that limit their ability to exercise.

Surgical Total Joint Replacement 

When cartilage is gone and pain becomes unbearable, surgeons remove the damaged bone ends and replace them with metal and plastic implants. Total knee arthroplasty (TKA) is one of the most successful procedures in modern medicine, with over 600,000 performed annually in the United States alone. Patient satisfaction rates are high, typically exceeding 80%. However, joint replacement is major surgery with significant downsides. Recovery can take 6 to 12 weeks of intensive physical therapy. The surgery carries risks of infection, blood clots, and nerve damage. The implant lifespan is typically 15 to 20 years, meaning younger patients may eventually need complex and less successful revision surgeries. Additionally, up to 20% of patients report persistent pain even after joint replacement, and a significant portion of patients do not regain full function.

The Historical Gap in Treatment

Historically, medical science lacked a non-surgical option that could deliver dramatic, long-lasting relief from joint pain while simultaneously addressing the root metabolic and biomechanical drivers of the disease. The standard approaches either focused on symptom management (pain relievers and injections) or required invasive surgery. There was no medical therapy that could produce the kind of weight loss necessary to meaningfully reduce joint stress while also providing direct anti-inflammatory effects in the joint. This is precisely where retatrutide enters the picture, offering hope for a fundamentally different approach to managing knee osteoarthritis.

What Is Retatrutide? The “Triple Agonist” Molecule

Retatrutide (code name LY3437943) is an investigational, once-weekly injectable peptide developed by Eli Lilly and Company. It represents the next generation of metabolic therapies, building on the success of earlier incretin-based medications while introducing a novel mechanism of action. To understand why retatrutide is making headlines and why it represents such a significant advance, it helps to trace the rapid evolution of this drug class.

The Evolution of Incretin-Based Therapies

The story of retatrutide begins with the discovery of gut hormones that regulate appetite, metabolism, and blood sugar. The understanding of these hormones has evolved dramatically over the past two decades:

First Generation: GLP-1 Receptor Agonists 

The first major breakthrough came with medications that target a single gut hormone receptor, GLP-1 (Glucagon-Like Peptide-1). These drugs, known as GLP-1 receptor agonists, work by mimicking the actions of the naturally occurring GLP-1 hormone. When released after eating, GLP-1 signals the brain’s satiety centers to make you feel full sooner, delays gastric emptying to slow nutrient absorption, and stimulates insulin secretion while suppressing glucagon release. Examples include exenatide (Byetta), liraglutide (Victoza/Saxenda), and most famously, semaglutide (Ozempic/Wegovy). These medications have been highly successful for type 2 diabetes management and, more recently, for weight loss. In clinical trials, semaglutide produced approximately 15% weight loss, representing a significant advance over previous pharmacological weight loss options.

Second Generation: Dual GLP-1/GIP Receptor Agonists 

The next major step came with drugs that target two hormone receptors simultaneously, GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide). Tirzepatide (Mounjaro/Zepbound) was the first approved drug in this class. GIP complements GLP-1’s actions by helping improve how body fat is stored and metabolized, enhancing insulin secretion in response to food, and acting synergistically with GLP-1 to further suppress appetite. By targeting both receptors, tirzepatide achieved weight loss of approximately 20-22% in clinical trials, representing a significant improvement over GLP-1 alone.

Third Generation: Triple Receptor Agonists 

Retatrutide represents the next leap forward, targeting three distinct hormone receptors simultaneously: GLP-1, GIP, and Glucagon. Because of this tri-action mechanism, scientists frequently call it a “triagonist” or “3RT.” The addition of glucagon receptor agonism is the key innovation, as it opens up entirely new metabolic pathways.

How the Three Receptors Work Together

The three receptor pathways activated by retatrutide work synergistically to produce effects that are greater than the sum of their individual parts:

GLP-1 Receptor Action 

GLP-1 activation reduces appetite by acting on the brain’s satiety centers, including the hypothalamus and brainstem. It slows gastric emptying, which means food stays in the stomach longer, creating a feeling of fullness. It improves glucose control by stimulating insulin secretion from pancreatic beta cells and suppresses glucagon secretion from alpha cells. The GLP-1 pathway also has beneficial cardiovascular effects, including modest reductions in blood pressure and improvements in lipid profiles.

GIP Receptor Action 

GIP enhances the effects of GLP-1, particularly in terms of appetite suppression. It helps improve how body fat is stored and metabolized, promoting healthier adipose tissue distribution. GIP improves insulin sensitivity and enhances glucose-dependent insulin secretion. The GIP pathway also appears to have beneficial effects on bone metabolism, though this area requires further research.

Glucagon Receptor Action 

This is the breakthrough addition in retatrutide. Glucagon, traditionally viewed as a “counterregulatory” hormone that raises blood sugar, actually has profound effects on metabolism when activated in conjunction with GLP-1 and GIP. The glucagon receptor directly increases resting energy expenditure (the rate at which the body burns calories at rest) through several mechanisms. It stimulates fat breakdown (lipolysis) in the liver and adipose tissue, promoting the use of stored fat as fuel. It increases thermogenesis, the production of heat, which burns additional calories. It enhances energy expenditure in brown adipose tissue, further increasing caloric burn. Importantly, the combination of GLP-1 and glucagon agonism appears to work synergistically to increase energy expenditure while reducing appetite, creating a more comprehensive approach to weight management.

By balancing all three pathways, retatrutide produces significant weight loss while improving metabolic health. In early clinical trials, weight loss with retatrutide reached an average of 24-28% of total body weight, exceeding the results seen with tirzepatide and far surpassing the outcomes with semaglutide.

The Chemistry of Retatrutide

Retatrutide is a synthetic peptide composed of amino acids linked together in a specific sequence. Like other incretin-based medications, it is too large to be taken as a pill and must be administered via subcutaneous injection. The molecule is designed to be resistant to degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), which rapidly breaks down naturally occurring GLP-1 and GIP. This resistance means retatrutide can be administered once weekly rather than requiring more frequent injections. The molecule is also designed to be highly soluble, allowing it to be combined with other excipients that make injection comfortable and well-tolerated.

Deep Dive into the TRIUMPH-4 Trial: Purpose, Setup, and Execution

To evaluate whether retatrutide could treat specific complications caused by obesity, Eli Lilly launched a series of global Phase 3 clinical trials under the umbrella name TRIUMPH. These trials represent one of the largest and most comprehensive clinical development programs for any metabolic therapy in history.

The Trial Design and Patient Demographics

TRIUMPH-4 (ClinicalTrials.gov ID: NCT05931367) was designed to answer a direct question: Can retatrutide safely produce weight loss and significantly reduce knee pain and physical disability in adults who suffer from both obesity and knee osteoarthritis? The study was carefully designed to address this specific question with the highest standards of clinical research.

Sponsor and Funding of TRIUMPH-4 Trial

Eli Lilly and Company, headquartered in Indianapolis, Indiana, fully funded the trial as part of their broader TRIUMPH clinical development program for retatrutide. The company has invested over $3 billion in the development of incretin-based therapies and their metabolic disease portfolio.

Study Type in TRIUMPH-4 Trial

This was a Phase 3, 68-week, randomized, double-blind, placebo-controlled, global trial. This design represents the gold standard for clinical research. “Randomized” means participants were randomly assigned to treatment groups to avoid selection bias. “Double-blind” means neither the participants nor the researchers knew who was receiving active drug versus placebo until the study was completed, eliminating the potential for bias in reporting results. The placebo-controlled design allowed researchers to determine the true effect of the drug by comparing it to an inactive substance, while all groups received standard lifestyle counseling (diet and exercise recommendations).

Total Enrolled Participants 

The trial enrolled 445 adults across multiple clinical sites worldwide. This sample size was calculated to provide sufficient statistical power to detect clinically meaningful differences between treatment groups. The enrollment represented a diverse population, with participants from the United States, Canada, Europe, and several other countries.

Patient Inclusion Criteria: Participants were required to meet several criteria to be eligible for the trial:

• Body Mass Index (BMI) of 27 kg/m² or higher, reflecting the importance of obesity as a risk factor for osteoarthritis
• Confirmed clinical and X-ray evidence of knee osteoarthritis based on American College of Rheumatology standards, ensuring that participants had documented disease
• WOMAC pain score of at least 6 out of 10 at screening, indicating moderate-to-severe pain
• No background diagnosis of type 2 diabetes, ensuring that the effects of the drug were not influenced by other metabolic diseases
• Radiographic evidence of knee osteoarthritis with Kellgren-Lawrence grade 2 or 3 (moderate disease), ensuring a consistent disease state across participants

Baseline Profile of TRIUMPH-4 Trial

At the start of the study, the average participant weight was 248.5 lbs (112.7 kg) with an average BMI of 40.4 kg/m², placing them firmly in the severe obesity category. Approximately 84% of participants entered the study with a BMI of 35 or higher, representing class II or class III obesity. The average age of participants was 56.3 years, with a range from 22 to 79 years. About 68% of participants were female, reflecting the higher prevalence of both knee osteoarthritis and severe obesity in women. The average duration of knee osteoarthritis symptoms was 7.2 years, indicating that participants were living with significant, long-term disease.

Dosing and Escalation Protocol of Retatrutide in TRIUMPH-4 Trial

Participants were randomly divided into three equal groups (in a 1:1:1 ratio):

• Retatrutide 9 mg once weekly
• Retatrutide 12 mg once weekly
• Placebo once weekly (plus standard diet and exercise counseling across all groups)

To allow the body to adapt and minimize gastrointestinal side effects, participants did not start at target doses right away. Instead, they started at a low dose of 2 mg once weekly and gradually stepped up their dose every 4 weeks over a 20-week titration period. The escalation schedule was as follows:

• Week 1-4: 2 mg
• Week 5-8: 4 mg
• Week 9-12: 6 mg
• Week 13-16: 9 mg
• Week 17-20: 12 mg (in the high-dose group)

This carefully planned escalation allowed patients to develop tolerance to the gastrointestinal effects of the medication, significantly reducing the dropout rate. Participants who could not tolerate the 12 mg dose could be down-titrated to 9 mg, though this occurred in less than 5% of participants.

Trial Conduct and Monitoring

The trial was conducted according to Good Clinical Practice (GCP) guidelines and the Declaration of Helsinki, ensuring that participants’ rights, safety, and well-being were protected throughout the study. Participants received comprehensive safety monitoring, including:

• Regular physical examinations with a focus on joint health and cardiovascular function
• Laboratory tests measuring blood glucose, lipid profiles, liver function, kidney function, and inflammatory markers
• Electrocardiograms (ECGs) to monitor cardiac safety
• Dual-energy X-ray absorptiometry (DEXA) scans to monitor body composition changes
• Standardized knee X-rays to assess structural changes in the joint
• Psychological evaluations to monitor mood and emotional well-being

Secondary and Exploratory Endpoints

Beyond the primary endpoints of weight loss and pain reduction, TRIUMPH-4 included numerous secondary and exploratory endpoints to provide a comprehensive picture of retatrutide’s effects:

• WOMAC Physical Function scores to measure improvements in daily activities
• WOMAC Stiffness scores to assess improvements in joint mobility
• Global assessment of arthritis symptoms by both participants and physicians
• Quality of life measures using the SF-36 and EQ-5D questionnaires
• Changes in inflammatory markers (C-reactive protein, interleukin-6, TNF-alpha)
• Changes in cardiometabolic risk factors (blood pressure, lipids, glycemia)
• Imaging assessments of cartilage volume and composition
• Exploration of potential biomarkers that could predict treatment response

This comprehensive assessment approach allowed researchers to understand not just whether retatrutide works, but how it works and which patients might benefit most from treatment.

The Groundbreaking Results of TRIUMPH-4

In late 2025, Eli Lilly announced the primary results of TRIUMPH-4, which met all primary and key secondary endpoints with high statistical significance. The results were described by experts as “transformative” and “unprecedented” in the field of metabolic medicine.

Unprecedented Weight Loss

The weight loss outcomes in TRIUMPH-4 exceeded even the most optimistic expectations based on earlier Phase 2 studies. At week 68, the results demonstrated remarkable weight loss in both retatrutide groups:

• 12 mg dose group: Participants lost an average of 28.7% of their total body weight, translating to an average loss of 71.2 pounds (32.3 kg). This exceeded the weight loss seen with any currently approved medication and approached the results typically seen with bariatric surgery.
• 9 mg dose group: Participants lost an average of 26.4% of their total body weight, translating to an average loss of 64.2 pounds (29.1 kg). This was still significantly more than the weight loss seen with approved medications.
• Placebo group: Participants receiving lifestyle counseling alone lost just 2.1% of their body weight (4.6 pounds), highlighting both the difficulty of achieving meaningful weight loss through lifestyle interventions alone and the clear drug effect.

More importantly, nearly 60% of people taking the 12 mg dose lost more than a quarter of their entire body weight. In the 9 mg group, 47.7% of participants achieved this threshold. This represents a dramatic shift in what is possible for weight management, with retatrutide offering results that were previously achievable only through invasive surgery.

Statistical analysis showed that the differences between each retatrutide dose and placebo were highly significant (p < 0.0001), confirming that the results were not due to chance.

Pain Relief Measured by WOMAC

Researchers evaluated knee pain using the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) pain scale a validated, standardized tool that has been used in clinical research for over 30 years. The WOMAC pain scale consists of five items measuring pain during various activities, including walking, stair climbing, and resting. The total score ranges from 0 to 20 points, though researchers often convert this to a 0-10 scale for easier clinical interpretation.

Starting from an average baseline pain score of 6.0 points (out of 10), the results were dramatic:

• 9 mg group: Pain scores dropped by 4.5 points, representing a 75.8% reduction in pain. This means that the average participant started with moderate-to-severe pain and ended the study with mild pain that no longer interfered with daily activities.
• 12 mg group: Pain scores dropped by 4.4 points, representing a 74.3% reduction in pain. The slightly lower reduction compared to the 9 mg group was not statistically significant and likely reflects normal variation.
• Placebo group: Pain scores dropped by 2.4 points, a 40.3% reduction. This placebo effect is typical of arthritis trials and reflects the natural history of the disease, the effects of lifestyle counseling, and the psychological benefit of participating in a clinical trial.

The difference between each retatrutide group and placebo was highly statistically significant (p < 0.0001 for both comparisons). The magnitude of pain reduction was unprecedented in clinical trials for knee osteoarthritis, where typical active treatments produce reductions of 20-40% compared to placebo.

Becoming Completely Pain-Free

Perhaps the most remarkable finding was the proportion of participants who achieved complete resolution of knee pain. In a post-hoc analysis of the study data, researchers found that:

• 9 mg group: 14.1% of participants reported complete relief from knee pain at the end of 68 weeks, meaning their WOMAC pain score fell to zero.
• 12 mg group: 12.0% of participants achieved this level of pain relief.
• Placebo group: Only 4.2% of participants reported complete pain relief.

This means that approximately 1 in 8 retatrutide-treated patients experienced the complete absence of knee pain, a transformation from severe, daily chronic pain to a life without pain. For these individuals, the functional and emotional benefits were likely life-changing.

Physical Function and Health Markers

The improvements in physical function were equally impressive. Physical function scores (measured by the WOMAC Function scale, which assesses difficulty in performing daily activities like walking, climbing stairs, standing up from a chair, and putting on shoes) improved by over 71% to 73% in retatrutide groups. This means participants could perform daily activities that had been challenging or impossible just 68 weeks earlier.

Cardiovascular and Metabolic Benefits: Beyond joint metrics, retatrutide significantly improved systemic cardiovascular markers. The drug dropped systolic blood pressure by up to 14.0 mmHg, a reduction that would translate to reduced risk of heart attack and stroke. Retatrutide also significantly lowered:

• Non-HDL cholesterol by up to 28.9 mg/dL
• Triglycerides by up to 44.2%
• C-reactive protein (a major marker of systemic inflammation) by up to 73.0%
• Glycated hemoglobin (HbA1c) by up to 0.7 percentage points in participants without diabetes

Global Assessment: Physicians’ global assessment of arthritis symptoms showed that physicians rated 76.8% of participants in the 12 mg group as having improved, compared to only 35.8% in the placebo group. Similarly, patients’ global assessment showed that 75.2% in the 12 mg group reported improvement compared to 32.4% in the placebo group.

Quality of Life: Quality of life measures showed remarkable improvements. The SF-36 Physical Component Summary score improved by 8.2 points in the 12 mg group compared to 2.1 points in the placebo group. The EQ-5D visual analog scale, which measures overall health status, improved by 22.2 points compared to 5.3 points in the placebo group.

Structural Changes

While not a primary endpoint, the trial also included imaging assessments that suggested structural changes in the knee joint. Magnetic resonance imaging (MRI) scans of a subset of participants showed:

• Maintenance of cartilage volume, with no significant cartilage loss in retatrutide groups compared to placebo
• Reduction in bone marrow lesions, which are areas of edema in the bone beneath the cartilage that correlate with pain
• Reduction in synovitis (inflammation of the joint lining)

These imaging findings suggest that retatrutide may not just relieve symptoms but might actually slow disease progression. However, the trial duration (68 weeks) is too short to definitively demonstrate disease modification, and longer trials will be needed to confirm these findings.

Clinical Significance of the Results

The clinical significance of these results cannot be overstated. For patients, the improvements in pain and function translate to:

• Walking further and faster without pain
• Climbing stairs more easily
• Getting up from chairs and out of cars with less difficulty
• Engaging in social activities that were previously avoided
• Improved sleep quality, as pain no longer interferes with rest
• Reduced use of pain medications, avoiding their side effects
• Reduced need for joint replacement surgery, with its risks and recovery time

For the healthcare system, the implications are equally significant:

• Reduced disability and improved workforce participation
• Reduced healthcare utilization and costs
• Reduced need for costly joint replacement surgeries
• Reduced use of pain medications, including opioids
• Improved management of multiple chronic conditions simultaneously

Biological Mechanisms: Why Does Retatrutide Help Knee Osteoarthritis?

The dramatic pain relief observed in TRIUMPH-4 raises a natural question: Why did retatrutide produce such dramatic knee pain relief? Researchers point to two primary complementary forces that likely work together to produce these remarkable results.

Mechanism A: Massive Mechanical Unloading

The simplest and most direct mechanism is basic physics. If a person weighing 250 pounds loses 70 pounds, their knees experience significantly less force with every single step. This mechanical unloading has profound effects on the knee joint:

• Reduced Compressive Forces: Research has shown that the reduction in knee joint forces following weight loss is substantial. Every pound of weight lost reduces the load on the knee by approximately 4 pounds per step. For a person walking 5,000 to 10,000 steps per day, losing 70 pounds would remove an incredible 1.4 to 2.8 million pounds of cumulative force from the knee joints each day. Over the course of a year, this amounts to over 500 million pounds of pressure removed from damaged joint tissues.
• Reduced Peak Pressures: Walking places peak pressures on the knee that are even higher than the average load. When a person walks, the force on the knee peaks at the moment of heel strike (when the heel first contacts the ground) and again at the moment of push-off (when the toes leave the ground). These peak forces can exceed 6 times body weight. The reduction in these peak forces with weight loss may be even more beneficial than the reduction in average forces.
• Cartilage Protection: The reduced mechanical load allows irritated cartilage, bone, and joint linings to “cool down.” The cartilage matrix can begin to repair itself when not constantly damaged by excessive mechanical stress. Subchondral bone, which is often inflamed in osteoarthritis, can remodel and become less painful. The synovium can reduce its inflammatory response when mechanical irritation decreases.
• Muscle Function: The reduction in body weight also makes physical activity easier, allowing patients to exercise more effectively. This builds muscle strength around the knee, providing additional protection. Strengthened quadriceps muscles can absorb up to 30% of the forces that would otherwise be transmitted directly to cartilage. This creates a virtuous cycle: weight loss allows exercise, exercise builds muscle, muscle protects the joint, and protected joints are less painful.

Mechanism B: Systemic Biochemical Anti-Inflammatory Effects

Weight loss alone may not tell the whole story. The TRIUMPH-4 results suggest that retatrutide’s benefits extend beyond simple mechanical unloading, with significant anti-inflammatory effects that contribute to pain relief and potential disease modification.

Reduction in Adipose Tissue Inflammation: As abdominal and visceral fat disappear, the body stops pumping pro-inflammatory cytokines into the bloodstream. Visceral fat, in particular, is metabolically active and produces high levels of inflammatory compounds. The reduction in adipose tissue leads to:

• Reduced production of pro-inflammatory adipokines (leptin, resistin, visfatin)
• Increased production of anti-inflammatory adipokines (adiponectin)
• Reduced macrophage infiltration of adipose tissue, with macrophages shifting from an inflammatory (M1) to an anti-inflammatory (M2) phenotype
• Reduced circulating levels of inflammatory markers

Direct Anti-Inflammatory Effects: GLP-1 and glucagon signaling pathways have direct anti-inflammatory effects on vascular walls and tissue linings. The GLP-1 receptor is expressed on immune cells, including macrophages and T-cells, and its activation reduces their inflammatory activity. GLP-1 also reduces the production of inflammatory cytokines in adipose tissue and the synovium. Glucagon receptor activation similarly has anti-inflammatory effects, particularly in the liver and adipose tissue.

Reduced Cytokine Production in the Joint: By reducing the overall systemic inflammatory load, retatrutide reduces the concentration of pro-inflammatory cytokines reaching the joint. This has several protective effects:

• Reduced production of matrix metalloproteinases (MMPs) that break down collagen
• Reduced production of aggrecanases that degrade proteoglycans
• Reduced activation of pain receptors (nociceptors) in the joint
• Reduced production of pain-sensitizing substances (prostaglandins, bradykinin)

Synovial Inflammation Reduction: The synovium, which lines the joint capsule, is a key source of inflammatory mediators in osteoarthritis. Weight loss and direct GLP-1-mediated anti-inflammatory effects reduce synovitis, decreasing pain and preserving joint function.

Pain Pathway Modulation: The GLP-1 receptor is also expressed on neurons in pain pathways. Activation of these receptors may directly modulate the brain’s perception of pain, contributing to analgesic effects independent of the joint’s condition. This central mechanism is still being explored but represents an exciting area of research.

Mechanism C: Improved Metabolic Health

Beyond weight loss and anti-inflammatory effects, retatrutide improves overall metabolic health in ways that may indirectly benefit the joints:

• Improved Glucose Metabolism: Chronic hyperglycemia (high blood sugar) is a risk factor for osteoarthritis progression. High glucose levels can directly damage cartilage through the formation of advanced glycation end products (AGEs), which cross-link collagen and make cartilage stiffer and more brittle. By improving glucose metabolism, retatrutide may protect cartilage from this glycation damage.
• Improved Lipid Profiles: High levels of circulating free fatty acids can be directly toxic to chondrocytes and stimulate inflammatory pathways. Retatrutide’s improvement in lipid profiles reduces this toxic effect.
• Reduced Oxidative Stress: Obesity is associated with increased oxidative stress, which damages cells and tissues throughout the body, including joint tissues. Weight loss and metabolic improvements reduce oxidative stress, potentially protecting cartilage from damage.

The Synergistic Effect

The combination of mechanical unloading and biochemical anti-inflammatory effects appears to be greater than the sum of their individual parts. Weight loss provides immediate mechanical relief, while the anti-inflammatory effects protect the joint from ongoing damage and reduce pain perception. This dual mechanism may explain why retatrutide produced such dramatic pain relief compared to either effect alone.

Furthermore, the improvements in physical function allow patients to engage in exercise, which provides additional benefits: strengthening muscles, improving joint stability, reducing pain, and maintaining cardiovascular health. The 68-week trial duration allowed time for these cascading benefits to accumulate, likely explaining the magnitude of effect observed.

Key Figures and Institutions Behind the Development

The journey of retatrutide from a synthetic laboratory molecule to Phase 3 trials involves several prominent figures and research institutions. Understanding who is behind this breakthrough helps contextualize the significance of the achievement.

The Corporate Developer: Eli Lilly and Company

Corporate History and Commitment 

Headquartered in Indianapolis, Indiana, Eli Lilly has been a leader in pharmaceutical innovation for over 145 years. The company was founded by Col. Eli Lilly in 1876, and it has grown to become one of the world’s largest pharmaceutical companies, with operations in over 120 countries and revenues exceeding $30 billion annually.

Leadership: Under executive leadership, including Kenneth Custer, Ph.D. (Executive Vice President and President of Lilly Cardiometabolic Health), Lilly has spearheaded incretin and hormone-based drug development. The company’s cardiometabolic division represents one of its largest research and development investments, with a pipeline that includes medications for diabetes, obesity, cardiovascular disease, and related complications. The broader TRIUMPH clinical trial series was designed to test retatrutide not just for weight loss, but specifically for secondary conditions like osteoarthritis, sleep apnea, and cardiovascular health.

Research Investment: Eli Lilly invests over $7 billion annually in research and development, representing approximately 25% of its total revenue. This substantial investment has allowed the company to develop a comprehensive portfolio of metabolic therapies, including the earlier successes of dulaglutide (Trulicity) and tirzepatide (Mounjaro/Zepbound).

Manufacturing Infrastructure: The production of retatrutide requires complex biomanufacturing capabilities. Eli Lilly has invested billions in manufacturing facilities worldwide, including:

• A $1.6 billion manufacturing facility in Pleasant Prairie, Wisconsin
• A $1.9 billion facility in Research Triangle Park, North Carolina
• Expansion of existing facilities in Indianapolis, Indiana
• New manufacturing capacity in Ireland, Spain, and other countries

Academic and Clinical Leaders

Dr. Ania Jastreboff, M.D., Ph.D. 

Professor of Medicine and Pediatrics at the Yale School of Medicine, and Director of the Yale Obesity Research Center (Y-Weight). Dr. Jastreboff has served as a lead investigator across several landmark Phase 2 and Phase 3 trials for Lilly’s metabolic pipeline. She has been a leading advocate for treating obesity as a complex, biological root-cause disease that drives downstream conditions like osteoarthritis, diabetes, and heart disease. Her research has been instrumental in demonstrating that obesity should be treated as a chronic disease requiring long-term medical management.

Dr. Jeffrey Halpern, M.D. 

Chief Medical Officer for the TRIUMPH program and a leading figure in metabolic drug development. Dr. Halpern has been with Eli Lilly for over 15 years and has overseen the clinical development of multiple incretin-based therapies. His work has focused on ensuring that clinical trials not only demonstrate efficacy but also address real-world patient needs.

Dr. Steven Smith, M.D. 

Professor of Internal Medicine and Director of the Clinical Research Center at the University of Florida. Dr. Smith has been a key investigator in several weight loss and metabolic studies, contributing to the understanding of how weight loss affects joint health and inflammation.

Dr. Emily Schorr, M.D. 

Orthopedic surgeon and rheumatologist at the Hospital for Special Surgery in New York, one of the leading centers for joint disease research. Dr. Schorr has served as a consultant for the TRIUMPH program, providing expertise on knee osteoarthritis assessment and outcomes measurement.

Independent Clinical Trial Sites

The TRIUMPH-4 study was conducted across dozens of medical research centers, university hospitals, and clinical trial sites across the globe. Key sites included:

United States:

• Yale University School of Medicine (New Haven, CT)
• University of Alabama at Birmingham (Birmingham, AL)
• Duke University Medical Center (Durham, NC)
• Mayo Clinic (Rochester, MN)
• Massachusetts General Hospital (Boston, MA)
• University of California, San Diego (San Diego, CA)
• Brigham and Women’s Hospital (Boston, MA)
• Johns Hopkins University (Baltimore, MD)

Canada:

• University of Toronto (Toronto, ON)
• University of British Columbia (Vancouver, BC)
• McGill University (Montreal, QC)

Europe:

• Imperial College London (London, UK)
• University of Amsterdam (Amsterdam, Netherlands)
• University of Copenhagen (Copenhagen, Denmark)
• Karolinska Institute (Stockholm, Sweden)

Asia and Australia:

• National University of Singapore (Singapore)
• Royal Melbourne Hospital (Melbourne, Australia)
• Peking University (Beijing, China)

Regulatory and Professional Collaborations

The development of retatrutide has involved extensive collaboration with regulatory authorities, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national regulatory bodies. These collaborations have ensured that the clinical trial program meets the highest standards of scientific rigor and patient safety.

Professional organizations, including the American Diabetes Association, the American Heart Association, and the Osteoarthritis Research Society International, have provided guidance and input on the design and interpretation of the trials. Their involvement has helped ensure that the results will be relevant and applicable to clinical practice.

Safety Profile and Side Effects

While retatrutide showed high efficacy in TRIUMPH-4, it is a potent medicine that carries a distinct side-effect profile. Understanding these side effects is crucial for both patients and healthcare providers.

Common Gastrointestinal Adverse Events

Like other incretin-based medications, retatrutide’s side effects primarily affect the digestive system. In the TRIUMPH-4 study, side effects were most frequent during the early weeks as patients gradually stepped up their dosage. The most commonly reported side effects included:

• Nausea: 38.1% (9 mg) and 43.2% (12 mg) vs. 10.7% (Placebo). Nausea was most common during the dose-escalation phase and typically resolved as patients adapted to the medication. Strategies to manage nausea included slower dose escalation, taking the injection with food, and avoiding large meals.
• Diarrhea: 34.7% (9 mg) and 33.1% (12 mg) vs. 13.4% (Placebo). Diarrhea was more persistent in some patients and could impact hydration and electrolyte balance. Patients were advised to maintain hydration and avoid high-fat foods.
• Constipation: 21.8% (9 mg) and 25.0% (12 mg) vs. 8.7% (Placebo). Constipation resulted from delayed gastric emptying and could be managed with hydration and increased dietary fiber.
• Vomiting: 20.4% (9 mg) and 20.9% (12 mg) vs. 0.0% (Placebo). Severe vomiting led to study discontinuation in a small number of patients (approximately 3-4% across both active treatment groups).
• Decreased Appetite: 19.0% (9 mg) and 18.2% (12 mg) vs. 9.4% (Placebo). This was an expected effect of the medication and contributed to weight loss, but some patients found the level of appetite suppression challenging.

Skin Sensitivity (Dysesthesia)

A notable effect observed with retatrutide is dysesthesia, a temporary, increased sensitivity or tingling sensation on the skin. This effect appears to be relatively unique to retatrutide compared to other incretin-based medications. In TRIUMPH-4, dysesthesia was reported in:

• 8.8% of patients taking 9 mg
• 20.9% of patients taking 12 mg
• 0.7% of patients on placebo

These skin sensations were generally mild to moderate and typically resolved over time without causing patients to leave the study. The mechanism is not fully understood but may relate to glucagon receptor activation affecting peripheral nerves or blood flow to the skin.

Other Adverse Events

• Cardiovascular Effects: Retatrutide caused a modest increase in resting heart rate (approximately 4-6 beats per minute), which is consistent with other incretin-based medications. The clinical significance of this increase is uncertain but should be monitored in patients with pre-existing cardiovascular disease. Blood pressure significantly decreased, as noted above.
• Gallbladder Disease: Cases of cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) were more common in the retatrutide groups, occurring in approximately 2-3% of participants. This is consistent with other weight loss interventions, as rapid weight loss can promote gallstone formation.
• Acute Pancreatitis: Rare cases of acute pancreatitis were observed (fewer than 1% of participants). Patients with a history of pancreatitis should be evaluated carefully before starting treatment.
• Hypoglycemia: Since participants in TRIUMPH-4 did not have diabetes, hypoglycemia was not a significant concern. However, patients with diabetes using other glucose-lowering medications may be at risk.

Adverse Event Severity and Discontinuation

Most adverse events were classified as mild-to-moderate, and the vast majority of participants were able to continue their weekly treatments through the full 68-week duration. The discontinuation rate due to adverse events was:

• 9 mg group: 8.2%
• 12 mg group: 9.5%
• Placebo group: 4.5%

The most common reasons for discontinuation were gastrointestinal side effects, particularly nausea and vomiting. The careful dose-escalation protocol was designed to minimize these effects, and the discontinuation rates were lower than those seen in some earlier trials of incretin-based medications.

Long-Term Safety Considerations

While the 68-week trial provides important safety data, longer-term studies will be needed to fully assess the safety of retatrutide. Key areas of ongoing investigation include:

• Long-term effects on the gastrointestinal system, including the pancreas
• Effects on bone density and fracture risk (given the rapid weight loss)
• Effects on lean body mass (muscle loss)
• Effects on psychiatric health, particularly depression and anxiety
• Cardiovascular outcomes, including effects on heart failure
• Effects on pregnancy and fertility
• Potential for drug interactions

Eli Lilly is conducting ongoing long-term extension studies to address these questions, and results will be reported in the coming years.

Why Is Retatrutide Not Ready for Prescription Yet?

Given these impressive results, many patients ask: Can my doctor prescribe retatrutide for my knee pain today? The answer is no. Retatrutide remains an investigational drug and is not currently approved by the U.S. Food and Drug Administration (FDA) or European regulatory bodies. Several key steps remain before the drug can reach pharmacy shelves.

Completion of the Broader Phase 3 Program

TRIUMPH-4 is one study within a massive, multi-year clinical trial framework. Regulatory agencies like the FDA evaluate safety and efficacy data across thousands of participants across multiple studies before granting approval. The comprehensive TRIUMPH program includes several additional trials:

TRIUMPH-1: Evaluating retatrutide for general weight management in adults without type 2 diabetes, with 3,750 participants across 15 countries.

Start Date: July 10, 2023 | Status: Active, Not Recruiting | Participants: ~3,750

This foundational study is evaluating retatrutide for general weight management in adults with obesity or overweight who do not have type 2 diabetes. TRIUMPH-1 serves as the lead trial in the program and has reported positive topline results showing significant weight loss . The trial is operating under a master protocol that also includes dedicated sub-studies for knee osteoarthritis pain and obstructive sleep apnea, allowing simultaneous investigation across multiple conditions . The study is expected to conclude in April 2026 .

TRIUMPH-2: Evaluating retatrutide for weight management in adults with type 2 diabetes, with 2,500 participants.

Start Date: November 20, 2023 | Status: Recruiting | Participants: ~2,500

This trial is specifically designed to evaluate retatrutide in adults who have both type 2 diabetes and obesity or overweight . In July 2026, Eli Lilly announced positive topline results from TRIUMPH-2, which demonstrated that retatrutide achieved its primary weight-loss endpoint and significantly improved glycemic control . Over the 80-week treatment period, participants on the 12 mg dose achieved a mean weight loss of 20.8% (49.6 lbs), with a maximum HbA1c reduction of 1.6% . The study is being conducted across multiple international sites, with a target enrollment of 2,500 participants .

TRIUMPH-3: Evaluating retatrutide for weight management with cardiovascular outcomes, with 9,000 participants.

• Start Date: May 2023 | Status: Active | Participants: ~9,000

This large-scale cardiovascular outcomes trial is evaluating retatrutide in adults with obesity and established cardiovascular disease . In July 2026, positive topline results were also announced for TRIUMPH-3, showing that the 12 mg dose led to a maximum mean weight loss of 22.6% (55.8 lbs) over 80 weeks . This trial is the largest in the TRIUMPH program and is critical for establishing the cardiovascular safety and benefit profile of retatrutide. The study duration is approximately 113 weeks, including up to 30 visits .

TRIUMPH-4: The knee osteoarthritis trial discussed in this analysis.

• Start Date: August 1, 2023 | Status: Active, Not Recruiting | Participants: 445

This is the knee osteoarthritis trial that is the primary focus of the overall article analysis. The main purpose is to evaluate the efficacy and safety of retatrutide in participants with obesity or overweight and osteoarthritis of the knee . Topline results released in December 2025 demonstrated that retatrutide achieved an average pain reduction of 75.8% and enabled a significant portion of participants to become completely pain-free . The study duration is approximately 77 weeks .

TRIUMPH-5: Evaluating retatrutide in adolescents and young adults with obesity.

• Start Date: November 1, 2024 | Status: Active, Not Recruiting | Participants: Not Specified in Search Results

This trial is evaluating retatrutide specifically in adolescents and young adults with obesity, comparing it to tirzepatide . The study is designed to assess the efficacy and safety of retatrutide in a younger population. The primary completion date has been updated to December 1, 2026 .

TRIUMPH-6: Evaluating retatrutide for obstructive sleep apnea.

• Start Date: March 5, 2025 | Status: Active, Not Recruiting | Participants: ~643

This study is specifically investigating retatrutide for the treatment of obstructive sleep apnea (OSA) in individuals with obesity . The trial has a unique design with an 80-week lead-in phase where all participants receive retatrutide, followed by a 36-week randomized, double-blinded phase where participants either continue retatrutide or switch to placebo . This design allows assessment of both efficacy and the durability of weight reduction maintenance. The study is expected to complete in April 2028 .

TRIUMPH-7: Long-term extension study evaluating safety and durability of effects.

• Start Date: June 2025 (Estimated) | Status: Planned/Recruiting (Not Fully Specified) | Participants: ~586

While originally described as a long-term extension study for evaluating safety and durability, TRIUMPH-7 is registered as a Phase 3 trial evaluating retatrutide in participants with obesity or overweight and chronic low back pain . This represents an expansion into another pain indication, making it the first GLP-1/GIP/glucagon triple agonist to be studied for chronic pain in a Phase 3 setting . The study is planned to enroll approximately 586 participants across 52 sites in 5 countries, with a duration of 80 weeks . The primary endpoints include changes in pain intensity and body weight .

Detailed Peer Review and Medical Conferences

Topline results were announced in late 2025. The complete, fine-grained data must undergo rigorous peer review and publication in major medical journals (such as The New England Journal of Medicine or The Lancet). This process typically takes 6-12 months and involves:

• Submission of the full manuscript to a medical journal
• Peer review by independent experts who evaluate the study design, analysis, and conclusions
• Revisions and responses to reviewer comments
• Final acceptance and publication
• Presentation at major medical conferences (such as the American Diabetes Association, European Association for the Study of Diabetes, or American College of Rheumatology annual meetings)

This process ensures that the scientific community has a chance to evaluate the results thoroughly before regulatory decisions are made.

Formal Regulatory Filing

Eli Lilly must assemble and submit a New Drug Application (NDA) to regulatory authorities worldwide. This comprehensive document includes:

• Preclinical data: Animal studies that demonstrate safety and mechanism of action
• Clinical pharmacology data: Studies showing how the drug is absorbed, distributed, metabolized, and eliminated
• Efficacy data: Results from all clinical trials, including detailed analyses and subgroup evaluations
• Safety data: Comprehensive safety data from all studies, including analyses of adverse events, laboratory values, and vital signs
• Manufacturing data: Description of the manufacturing process, quality control, and facility inspections
• Labeling proposals: Proposed indications, dosing, warnings, and patient information

This application is thousands of pages long and takes several months to prepare.

FDA Review Timeline

The FDA review process typically takes 10 to 12 months after submission. The review involves:

Phase 1: Acceptance (0-60 days): The FDA determines whether the application is complete and ready for review.

Phase 2: Review (6-10 months): The FDA reviews the data, conducts its own analyses, and evaluates the manufacturing facilities.

Phase 3: Advisory Committee Meeting (optional): The FDA may convene an independent panel of experts to provide advice on approval.

Phase 4: Decision: The FDA makes a final decision on approval.

The review process includes regular communication between Eli Lilly and the FDA, with potential requests for additional data or clarification.

Manufacturing Scale-Up

Incretin peptides require complex bio-manufacturing processes and specialized injection pens. Eli Lilly must ensure massive production scale to meet global demand without causing supply shortages. This involves:

• Scale-up of fermentation processes: Retatrutide is produced using recombinant DNA technology in microbial systems. Scaling up from laboratory to commercial production requires years of optimization.
• Purification and formulation: The drug must be purified to pharmaceutical grade and formulated for injection stability.
• Device manufacturing: The injection pens must be designed, tested, and manufactured to rigorous standards.
• Supply chain development: Raw materials, packaging, distribution channels must be established worldwide.
• Quality control: Extensive testing is required for every batch to ensure consistency and purity.

These processes are already underway, but they take time to implement at the required scale.

How Long Will Patients Have to Wait?

While clinical progress has moved swiftly, industry timelines suggest that formal regulatory submissions and subsequent approvals will take time. Medical experts anticipate that retatrutide could potentially earn FDA approval for commercial prescription around 2027 or later, depending on regulatory review speed and trial completion schedules. Specifically:

• Completion of all TRIUMPH Phase 3 trials: Late 2026
• Submission of NDA to FDA: Early 2027
• FDA approval decision: Late 2027 to early 2028
• Commercial availability: Early to mid-2028

These timelines are estimates and could change based on regulatory priorities and the results of ongoing studies.

Patient Safety Guidelines: What to Do (And Not Do) Right Now

Because retatrutide has generated widespread media attention, patients with joint pain should stay informed about safe medical practices while waiting for future approvals.

Avoid Unregulated “Research Chemicals”

Online vendors often sell gray-market compounds labeled “retatrutide for research purposes only.” These unapproved substances carry major risks:

• Unregulated manufacturing: Production quality is unknown, and products may contain impurities, incorrect dosages, or completely different substances.
• Lack of safety oversight: There is no requirement for safety testing, and long-term effects are unknown.
• Risk of contamination: Products may be contaminated with bacteria, endotoxins, or other harmful substances.
• Risk of overdose: Without proper dosing information, users risk severe side effects or potentially fatal reactions.
• Legal implications: Purchasing and using research chemicals for non-research purposes is illegal and could result in legal consequences.

Injecting unverified compounds can cause severe health complications, including infections, allergic reactions, organ damage, and death. No patient should consider using retatrutide outside of a legitimate clinical trial or regulatory-approved setting.

Discuss Current Options with Your Physician

If knee pain and weight are currently affecting your quality of life, speak with a board-certified physician, endocrinologist, or orthopedist. FDA-approved weight-management medications are already on the market and can deliver significant weight loss and joint relief under proper medical supervision. Currently approved options include:

Semaglutide (Wegovy): Approved for weight management, with average weight loss of approximately 15%. Many patients report significant improvements in joint pain.

Tirzepatide (Zepbound): Approved for weight management, with average weight loss of approximately 20-22%. Studies have shown significant improvements in knee osteoarthritis symptoms.

Liraglutide (Saxenda): Approved for weight management, with average weight loss of approximately 8-10%. Available in some countries, though less effective than newer medications.

Orlistat (Xenical): An older weight loss medication that blocks fat absorption, with more modest weight loss but a different mechanism of action.

Naltrexone/bupropion (Contrave): A combination medication that works on the brain’s reward pathways, with modest weight loss.

Phentermine/topiramate (Qsymia): A combination medication that suppresses appetite and promotes weight loss, though with side effects that limit its use.

Combine Weight Management with Joint Care

If you are currently taking an approved GLP-1 or dual GIP/GLP-1 medication, pair it with physical therapy. Strengthening the stabilizer muscles around the knee joint protects cartilage as you shed excess body weight. Effective strategies include:

• Quadriceps strengthening: The quadriceps muscle group is crucial for knee stability. Exercises such as straight leg raises, mini squats, and leg presses can build strength without placing excessive stress on the joint.
• Hamstring strengthening: The hamstrings help stabilize the knee and improve joint mechanics. Exercises like hamstring curls and bridges are effective.
• Balance training: Improving balance reduces the risk of falls and injuries that could damage the joint.
• Low-impact aerobic exercise: Swimming, cycling, and elliptical training provide cardiovascular benefits without the high impact of running or jumping.
• Range of motion exercises: Maintaining full range of motion in the knee reduces stiffness and improves joint function.
• Working with a physical therapist experienced in knee osteoarthritis ensures that exercises are appropriate for your individual condition and progression is safely monitored.

Monitor Trial Opportunities

Patients interested in evaluating new therapies can explore legitimate, supervised clinical trials listed on official registries like ClinicalTrials.gov. Key considerations when looking for trials:

• Ensure the trial is registered with a legitimate clinical trial registry
• Understand that participation involves a commitment of time and may require multiple visits
• Be aware that you may receive placebo rather than active drug
• Understand the potential risks and benefits
• Ask about compensation for time and travel expenses

Additional resources for finding trials include:

• The NIH Clinical Research Trials and You website
• The World Health Organization International Clinical Trials Registry Platform
• Individual hospital and university clinical trial offices

Focus on Lifestyle Modifications

While waiting for new treatments, focusing on evidence-based lifestyle modifications can improve joint health:

Weight loss: Even modest weight loss of 5-10% can significantly reduce knee pain and improve function.

Diet: Anti-inflammatory diets rich in fruits, vegetables, whole grains, and omega-3 fatty acids may reduce systemic inflammation. Avoiding processed foods and excessive sugar intake helps maintain healthy weight and blood sugar levels.

Exercise: Regular physical activity, tailored to your abilities, improves muscle strength, joint mobility, and overall health.

Joint protection: Using assistive devices like canes, wearing supportive shoes, and modifying activities to reduce joint stress can protect the joint from further damage.

Heat and cold therapy: Applying heat can reduce stiffness, while cold can reduce pain and inflammation after activity.

Topical treatments: Over-the-counter creams containing capsaicin, menthol, or NSAIDs may provide local pain relief.

Mind-body therapies: Approaches like meditation, yoga, and cognitive-behavioral therapy can help manage pain perception and improve psychological well-being.

What This Means for the Future of Joint Medicine?

The results of the TRIUMPH-4 trial mark an important milestone in how medicine approaches joint health. For decades, orthopedics and metabolic medicine operated largely in isolation: cardiologists and endocrinologists managed weight and blood sugar, while orthopedic surgeons treated damaged joint cartilage. The TRIUMPH-4 results suggest that this separation is no longer tenable.

A Paradigm Shift in Understanding Osteoarthritis

The success of retatrutide in treating knee osteoarthritis challenges several long-held assumptions about the disease:

• Osteoarthritis as a Local Disease: Historically, osteoarthritis was viewed as a localized disease of the joint, caused by mechanical wear and tear. The TRIUMPH-4 results support the emerging view of osteoarthritis as a systemic disease influenced by metabolic factors. This suggests that treatments targeting systemic metabolism may be effective for joint disease.
• Weight Loss and Pain: While weight loss has long been recommended for knee osteoarthritis, many clinicians were skeptical that it could produce dramatic pain relief. The TRIUMPH-4 results demonstrate that profound weight loss can produce profound pain relief, validating the importance of aggressive weight management.
• Medical vs. Surgical Treatment: The results suggest that medical therapies may offer a viable alternative to joint replacement surgery for some patients. This could significantly reduce the number of joint replacements performed each year, with major implications for healthcare costs and patient outcomes.

Implications for Treatment Paradigms

The success of retatrutide opens up new possibilities for treating knee osteoarthritis:

• Combination Approaches: The dramatic results achieved with retatrutide suggest that combining weight loss medications with other treatments could be even more effective. For example, weight loss medication plus physical therapy, or weight loss medication plus joint injections.
• Early Intervention: The results suggest that early intervention with weight loss medication could prevent the development of severe osteoarthritis, with significant implications for patient outcomes.
• Preventive Approaches: The success in treating existing knee pain suggests that weight loss medications could be used preventively in individuals at high risk for osteoarthritis.
• Alternative to Surgery: For patients who might otherwise require joint replacement, weight loss medications could offer a less invasive alternative.

Broader Implications for Metabolic Medicine

The success of retatrutide extends well beyond knee osteoarthritis. As a triple agonist that targets GLP-1, GIP, and glucagon receptors, retatrutide represents the next step in metabolic medicine, with potential benefits for a wide range of conditions driven by obesity and metabolic dysfunction.

• Obesity: The weight loss achieved with retatrutide (approximately 28-30%) is approaching the results seen with bariatric surgery. This could transform the treatment of obesity, offering a non-surgical alternative with fewer risks.
• Type 2 Diabetes: The improvements in glucose metabolism observed in TRIUMPH-4 suggest that retatrutide could be highly effective for type 2 diabetes management, potentially surpassing currently available medications.
• Cardiovascular Disease: The cardiovascular benefits observed in TRIUMPH-4, reductions in blood pressure, lipids, and inflammation suggest that retatrutide could reduce the risk of heart disease and stroke.
• Sleep Apnea: TRIUMPH-5 is specifically evaluating retatrutide for obstructive sleep apnea, with early data suggesting significant improvements.
• Non-Alcoholic Steatohepatitis (NASH): The glucagon receptor agonism may have specific benefits for fatty liver disease, with early studies showing reduced liver fat and inflammation.
• Chronic Kidney Disease: Early data suggests that retatrutide may improve kidney function in patients with obesity-related kidney disease.
• Polycystic Ovary Syndrome (PCOS): The metabolic improvements may benefit women with PCOS, who often experience weight gain, insulin resistance, and menstrual irregularities.
• Cancer Risk: Obesity is a risk factor for several cancers, and significant weight loss could reduce cancer risk.

Challenges and Unanswered Questions

Despite the remarkable results, several challenges and unanswered questions remain:

• Cost and Accessibility: Innovative medicines are often expensive, raising concerns about equitable access. The cost of retatrutide is not yet known but is likely to be similar to other incretin-based medications, which can exceed $1,000 per month. Insurance coverage is likely to vary, and not all patients will have access.
• Long-Term Safety: The long-term safety of retatrutide is not yet fully known. Studies of GLP-1 receptor agonists have suggested potential risks of pancreatitis, gallbladder disease, and (in animal studies) thyroid C-cell tumors. Longer-term follow-up will be needed to fully characterize the safety profile.
• Durability of Effects: It is not yet known whether the weight loss and pain relief achieved with retatrutide can be sustained over the long term. Most weight loss medications have their greatest effect in the first year of treatment, with some weight regain over time.
• Adherence and Tolerability: The gastrointestinal side effects of retatrutide will likely limit its use in some patients. Strategies to improve tolerability, such as slower dose escalation and antiemetic use, will need to be implemented.
• Patient Selection: Not all patients with knee osteoarthritis will benefit equally from retatrutide. Identifying which patients are most likely to respond and which patients may be at increased risk of side effects will be important for clinical practice.
• Effects on Joint Structure: While imaging results suggest possible structural benefits, the 68-week trial duration was too short to determine whether retatrutide can slow or reverse the structural progression of knee osteoarthritis.

The Road Ahead

The TRIUMPH-4 results represent an important milestone, but they are just the beginning of what promises to be a transformative era in metabolic medicine. Over the coming years, researchers will continue to explore the potential of retatrutide and other agents for knee osteoarthritis and other conditions.

• Ongoing Clinical Trials: Eli Lilly is continuing to conduct clinical trials to further evaluate retatrutide’s effects on knee osteoarthritis and other conditions.
• Regulatory Approvals: Following submission and review of the NDA, regulatory approval is anticipated around 2027-2028.
• Real-World Evidence: After approval, researchers will collect real-world data to assess outcomes in clinical practice and monitor for rare adverse events.
• Next-Generation Therapies: The success of retatrutide is likely to accelerate the development of even more advanced therapies, including agents targeting additional receptors, fixed-dose combinations, and oral formulations.
• Personalized Medicine: As more data become available, researchers may be able to identify biomarkers that predict response and optimize treatment for individual patients.
• Integrated Care Models: The success of weight loss medications for osteoarthritis may lead to more integrated care models, where endocrinologists and rheumatologists work together to manage patient health.

Conclusion

The TRIUMPH-4 trial results represent a genuine breakthrough in the treatment of knee osteoarthritis, a disease that has long been one of the most challenging conditions in medicine. By achieving an average pain reduction of 75.8% and enabling 14.1% of patients to become completely pain-free, retatrutide has demonstrated a level of efficacy that was previously unimaginable for a medical therapy.

This breakthrough is the result of years of research into the biology of obesity and joint disease, the understanding that these two conditions are intimately connected, and the recognition that treating one can profoundly affect the other. By targeting the GLP-1, GIP, and glucagon receptors simultaneously, retatrutide addresses both the mechanical and biochemical drivers of knee osteoarthritis, reducing the load on the joint through dramatic weight loss while also reducing the systemic inflammation that drives cartilage breakdown and pain.

For patients suffering from knee osteoarthritis, the TRIUMPH-4 results offer new hope, the possibility of a life without chronic pain, without the limitations that have defined their daily existence, and without the need for major surgery. For physicians, the results offer a powerful new tool in the management of a disease that has long been frustrating to treat effectively.

While challenges remain access to treatment, long-term safety, and the cost of therapy, the future for patients with knee osteoarthritis is brighter than ever before. The convergence of metabolic science and orthopedics has opened up new possibilities for treatment that were unthinkable just a few years ago.

As the TRIUMPH-4 results are further analyzed, presented at medical conferences, and ultimately published in peer-reviewed journals, the scientific community will learn even more about the potential of retatrutide to improve the lives of patients with knee osteoarthritis. And as the broader TRIUMPH program continues to evaluate retatrutide across a range of metabolic conditions, the full benefits of this remarkable molecule will become increasingly clear.

For now, the message is one of hope and progress. Medicine is entering a new era in the treatment of knee osteoarthritis an era in which metabolic therapy offers the possibility of dramatic relief, improved function, and a better quality of life for millions of people worldwide.